Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
AbstractGene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert nontoxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the bystander effect, leads to tumour regression. Here we discuss the implications of either striving for a strong bystander effect to overcome poor gene transfer, or avoiding the bystander effect to reduce potential systemic effects, with the aid of three successful GDEPT systems. This review concentrates on bystander effects and drug development with regard to these enzyme prodrug combinations, namely herpes simplex virus thymidine kinase (HSV-TK) with ganciclovir (GCV), cytosine deaminase (CD) from bacteria or yeast with 5-fluorocytodine (5-FC), and bacterial nitroreductase (NfsB) with 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), and their respective derivatives. View Full-Text
Share & Cite This Article
Dachs, G.U.; Hunt, M.A.; Syddall, S.; Singleton, D.C.; Patterson, A.V. Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy. Molecules 2009, 14, 4517-4545.
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy. Molecules. 2009; 14(11):4517-4545.Chicago/Turabian Style
Dachs, Gabi U.; Hunt, Michelle A.; Syddall, Sophie; Singleton, Dean C.; Patterson, Adam V. 2009. "Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy." Molecules 14, no. 11: 4517-4545.